Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (September 2017)
26 slides from Inspiremd's investor presentation, Sep 12, 2017
Slide 1: Investor Presentation
inspireMID Investor Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements inspireMD This presentation contains "forward-looking statements.” Such statements may be preceded by the words “intends,” "may," "wil," "plans," "expects,” "anticipates," “projects,” "predicts," "estimates," “aims,” "believes,” “hopes,” "potential" or similar words. Forwa
Slide 3: About InspireMD
About Inspire MD inspire InspireMD is a commercial-stage medical device company with proprietary and innovative embolic prevention systems (EPS)/thrombus management technologies and neurovascular devices that seek to overcome the harmful consequences of conventional stenting. technol logy in multipl
Slide 4: Embolization Following Carotid Artery Stenting
Embolization Following Carotid Artery Stenting inspireMD “Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolization,
Slide 5: Pre- and post-procedure carotid stenting outcomes with MRI
uenc a Range from Neurological (2) fe) AS no (0) Qa Ins} pire Pre-Procedure Post-Procedure Pre-intervention showing 90% occlusion of the Post-intervention showing successful opening carotid artery and an MRI showing an old white of the occluded carotid artery with conventional matter infarction (obs
Slide 6: MicroNet Prevents Distal Embolization and Other Vascular Disease Challenges
MicroNet™ Prevents Distal Embolization and ineake Other Vascular Disease Challenges inspire: + Ultrathin PET* mesh provides meaningful clinical benefit versus conventional devices + Provides revascularization benefit + MicroNet™ acts as a “safety net’ by offering greater vessel area coverage to prev
Slide 7: Conventional Carotid Stents vs CGuard EPS
- _ . e ove > ,arol ; nMenira ; uc inspire. Conventional Carotid Stents CGuard™ EPS No plaque coverage leading to vulnerable The MicroNet permanently covers thrombus that plaque protrusions or prolapse might be present and the plaque and prevents thrombus or “debris” from passing through the mesh an
Slide 8: Plaque Coverage with MicroNet
Plaque Coverage with MicroNet™ inspireMD jaa Intervention MicroNet mesh preventing prolapse “Tomayu eta Eupntncen 27
Slide 9: Large & Growing Addressable Market
Large & Growing Addressable Market inspireMD Embolic Prevention Products $500M v Carotid MGuard™* $1.7B vo Coronary AMI & SVG Planned NGuard™ $675M ‘Submission Neurovascular TBD Planned PVGuard™ eee $1.7B Submission Peripheral TBD CGuard™ * MGuard™ global strategy focused on drug eluting stent OEM p
Slide 10: Positive CGuard Clinical Experience
Positive CGuard™ Clinical Experience inspireMD CARENET Clinical Trial (2014) + 30 Patient Safety and Efficacy clinical trial + Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%") + 50% fewer new ischemic lesions with lesion volume being 10x times smaller compar
Slide 11: Additional Independent Clinical Data
Additional Independent Clinical inspireMD Independent study conducted in 30 patients with internal carotid artery disease Clinical results (2016) + 100% success in implanting the CGuard™ EPS + No peri- or post-procedural complications + No deaths, major adverse events, minor or major strokes, or new
Slide 12: Additional Independent Clinical Data: Iron-Guard Registry
Additional Independent Clinical Data inspireMD SPECIAL ARTICLES The Iron-Guard Registry * Ehysicies mated Physiclan-initiated prospective Italian Registry + 12 large Italian medical centers ‘of carotid stenting with the C-Guard mesh-stent: + 200 patients the IRON-Guard registry Rationale and design
Slide 13: Growing KOL Support Across Europe
Growing KOL Support Across Europe inspire Leipzig Interventional Course (LINC) January 2017 European Association of Percutaneous Cardiovascular Interventions (EuroPCR) May 2017 PD Dr. Andrej Schmidt and Dr. Sven Braunlich Department _Dr. Fausto Castriota and Dr. Antonio Micari interventional of Angi
Slide 14: EuroPCR 2017 Highlights
Peripheral Interventions: Pam EuroPCR 2017 Highlights _—_—«sAsspureMMD H Marco ROFFL, Switzerland Piotr MUSIALEK , Poland “We know that with the prior generation of [carotid] stents a lot of the [distal embolization] events happen after the procedure” (Prof. Musialek) “Here [with mesh covered stents
Slide 15: Impact of Mesh Covered Stents on Long Term Stroke Compared to Surgery
Impact of Mesh Covered Stents on Long term lost WID Stroke Compared to Surgery Inspire! Independent Clinical Review Authored by Leading U.S. and European Physicians Supports the Safety and Efficacy of CAS vs. CEA (2017) per “ Data from more than 550 patients: near-elimination ned sentient ou evr eld
Slide 16: Sales & Marketing Strategy
Sales & Marketing Strategy inspireMD Former distributor for Europe was primarily focused on the interventional neuroradiology market, their key customer segment Replaced exclusive European CGuard™ distributor with regional distributors who target all 4 clinical specialties + Vascular surgery, interv
Slide 17: Recent Highlights
Recent Highlights inspireMD v Completed transition from a single distributor covering 18 European countries, to a direct distribution model with local distributors v European distribution network now fully in place v Rapidly adding top key opinion leaders across Europe v CGuard sales in European cou
Slide 18: CGuard Product Development
CGuard™ Product Development + US FDA + Pre-IDE FDA submission for CGuard™ February 2017 + Formal FDA meeting held April 2017 FID / \ + Planned IDE submission in 2018 + Next generation CGuard™ - 5 French CGuard™ Minimally invasive devices trending smaller for broader and easier usage Lower profile sy
Slide 19: Broad Platform Technology
Broad Platform Technology inspireMD MGuard™ Coronary EPS RGuard™ CGuard™ Renal” Carotid EPS MicroNet™ Platform Technology NGuard™ PVGuard™ Peripheral” MGuard™ Drug Eluting” “planing 8 Oeveooment Pace rT
Slide 20: Near Term Growth Strategy
Near Term Growth Strategy CGuard™ Engaging distribution partners in countries with current/near-term regulatory approval Seeking additional regulatory approvals in countries that accept CE Mark Plan to file US FDA IDE in 2018 Plan to file CE Mark for next generation 5 French CGuard™ in 2018 Expandin
Slide 21: Recent/Upcoming Anticipated Milestones
Recent/Upcoming Anticipated Milestones v v (Guard launch in Russia: H4 2017 US. #22017 Guard 5 French Glas approval and Guard . i Jaunch in India submission Germany, aly, Spain, etc. v v 2018 ‘and Mexico: H2 2017 Continued market execution and revenue growth. (CGuard: 2018, ‘submission inspireMD WDE
Slide 22: Intellectual Property Portfolio
Intellectual Property Portfolio inspireMD + Proprietary platform technology supported by a robust intellectual property portfolio * Continue to strengthen and broaden patent protection globally to enable future pipeline products PATENT RIGHTS: ISSUED ALLOWED PENDING Rest of World 18 2 19
Slide 23: Leadership
Leadership Significant track records of success inspireMD TA \N ister Pate tion Sol Barer, Ph.D. Special Advisor to the Board President and CEO cBostone Prizey = @ [Pauistuns | Chama osns Fidelity Director Bettie Gsm LUTONIX Director ObteartFiow .,. Cordis. @j uanvare | scizaresno. | TZ Gen 2
Slide 24: Investment Highlights
Investment Highlights inspireMD « Multi-billion dollar opportunity for MicroNet™ products for multiple vascular markets + Current stents do not adequately address the risk of post-procedural embolization + Consistent positive clinical trial results positioning CGuard™ as a potential standard-of-care
Slide 25: Financial Snapshot
Financial Snapshot inspireMD NYSE MKT: NSPR Stock (9/8/17): ‘Average 3 Month Volume (9/8/17) Shares Outstanding (9/8/17) Shares Outstanding Including full conversion of preferred shares (9/8/17): Market Capitalization including full conversion of preferred shares (9/8/17) aM Total Cash (6/30/2017) $
Slide 26: InspireMD
inspireMD James Barry, Ph.D., President and CEO Craig Shore, CFO 888.776.6804 888.776.6804 jimb@inspiremd.com craigs@inspiremd.com